Click here to view the brief. SB 17 is a California law that regulates changes to a drug’s Wholesale Acquisition Cost (WAC) or list price.
Jeffrey S. Bucholtz, Ethan P. Davis, and Matthew V.H. Noller of King & Spalding LLP and the U.S. Chamber’s Litigation Center served as co-counsel for the U.S. Chamber.